Evidence map›Paper›PMID 20843955›Full record

ArticleMolecular pharmacology2010

The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels.

Heun Soh, Anastassios V Tzingounis

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Molecular pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Glial KCNQ KNeuron · 2024
    Article
  5. Article
  6. Article
  7. Chemical modulation of Kv7 potassium channels.RSC medicinal chemistry · 2021
    Review
  8. Review
  9. Insights into Cardiac IKs (KCNQ1/KCNE1) Channels Regulation.International journal of molecular sciences · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Heun SohDepartment of Physiology and Neurobiology, University of Connecticut, Storrs, CT 06269, USA.
Anastassios V Tzingounis
University of Connecticut · US

Funding

Molecular components of the calcium activated slow after hyperpolarizationR00NS060890 · NINDS · UNIVERSITY OF CONNECTICUT STORRS · PI TZINGOUNIS, ANASTASIOS · 2009 to 2010
$487k
Molecular components of the calcium activated slow after hyperpolarizationR01NS060890 · NINDS · UNIVERSITY OF CONNECTICUT STORRS · PI TZINGOUNIS, ANASTASIOS · 2008 to 2008
$249k
Molecular components of the calcium activated slow afterhyperpolarizationK99NS060890 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TZINGOUNIS, ANASTASIOS · 2008 to 2008
$79k
GENE THERAPY FOR HEPATITIS C INFECTION--CHRONIC INFECTIOUS DISEASE MODELZ01CL002077 · CLC · CLINICAL CENTER · PI SHIH, J W · 1996 to 1998
–
Intramural NIH HHS Z01 CL002077NINDS NIH HHS K99 NS060890NINDS NIH HHS NS060890NINDS NIH HHS R00 NS060890NINDS NIH HHS R01 NS060890
6 · The paper itself

Abstract

Mutations in members of the KCNQ channel family underlie multiple diseases affecting the nervous and cardiovascular systems. Despite their clinical relevance, research into these channels is limited by the lack of subtype-selective inhibitors, making it difficult to differentiate the physiological function of each family member in vivo. We have proposed that KCNQ channels might partially underlie the calcium-activated slow afterhyperpolarization (sAHP), a neuronal conductance whose molecular components are uncertain. Here, we investigated whether 3-(triphenylmethylaminomethyl)pyridine (UCL2077), identified previously as an inhibitor of the sAHP in neurons, acts on members of the KCNQ family expressed in heterologous cells. We found that 3 μM UCL2077 strongly inhibits KCNQ1 and KCNQ2 channels and weakly blocks KCNQ4 channels in a voltage-independent manner. In contrast, UCL2077 potentiates KCNQ5 channels at more positive membrane potentials, with little effect at negative membrane potentials. We found that the effect of UCL2077 on KCNQ3 is bimodal: currents are enhanced at negative membrane potentials and inhibited at positive potentials. We found that UCL2077 facilitates KCNQ3 currents by inducing a leftward shift in the KCNQ3 voltage-dependence, a shift dependent on tryptophan 265. Finally, we show that UCL2077 has intermediate effects on KCNQ2/3 heteromeric channels compared with KCNQ2 and KCNQ3 homomers. Together, our data demonstrate that UCL2077 acts on KCNQ channels in a subtype-selective manner. This feature should make UCL2077 a useful tool for distinguishing KCNQ1 and KCNQ2 from less-sensitive KCNQ family members in neurons and cardiac cells in future studies.

Indexed as

AnimalsBenzylaminesCHO CellsCricetinaeCricetulusDose-Response Relationship, DrugEpilepsyHEK293 CellsHumansKCNQ Potassium ChannelsMembrane PotentialsMiceMice, Inbred C57BLPotassium Channel BlockersPotassium Channels, Calcium-ActivatedPyridines3-(triphenylmethylaminomethyl)pyridineBenzylaminesKCNQ Potassium ChannelsPotassium Channel BlockersPotassium Channels, Calcium-ActivatedPyridines

Identifiers

PMID20843955
PMCPMC2993466
OpenAlexW2117411892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.